6. Parkinson disease Clinical trials / Disease details


Clinical trials : 2,307 Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

  
23 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000047341
2022/07/0131/03/2022Randomized controlled trial of the efficacy and feasibility of a mHealth-type dance program for people with Parkinson's disease.Randomized controlled trial of the efficacy and feasibility of a mHealth-type dance program for people with Parkinson's disease. - Randomized controlled trial of the efficacy and feasibility of a mHealth-type dance program for people with Parkinson's disease. Parkinson's diseaseThe dance exercise group will have one online lesson per week with a coach, 60 minutes (see Appendix for details) and 30 minutes of video dance (movement review and lesson) as a home trainer to perform the exercises.
The active control group was instructed to perform stretching, flexibility, and relaxation exercises (excluding strength, balance, aerobic, and functional training) three times a week for 30 minutes per session. These exercises were selected from several physical therapy programs created for persons with Parkinson's disease.
Department of Neurology, Fukuoka universityNULLPending30years-old75years-oldMale and Female60Not selectedJapan
2NCT05128175
(ClinicalTrials.gov)
October 29, 202127/10/2021Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed ConditionsAn Open-label, Balanced, Randomized, Five-treatment, Five-period, Five-sequence, Multiple Oral Dose, Crossover Comparative Bioavailability Study of Different Strengths of Carbidopa/Levodopa Extended-release Tablets With Carbidopa and Levodopa Tablets in Normal, Healthy Adult Human Subjects Under Fasting and Fed ConditionsParkinson DiseaseDrug: WD-1603 Carbidopa-Levodopa Extended-Release TabletsShanghai WD Pharmaceutical Co., Ltd.NULLRecruiting18 Years45 YearsAll15Phase 1India
3NCT05220072
(ClinicalTrials.gov)
August 28, 202118/11/2021Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of Carbon-14 BIA 28-6156 in Healthy Male SubjectsParkinson DiseaseDrug: Carbon-14 BIA 28-6156Bial R&D Investments, S.A.NULLCompleted30 Years65 YearsMale6Phase 1United Kingdom
4ChiCTR2000038852
2020-10-202020-10-07Study on the effect and mechanism of cognitive-cup-tapping-balance-training on fall prevention in community Parkinson's patients: a randomized controlled trialStudy on the effect and mechanism of cognitive-cup-tapping-balance-training on fall prevention in community Parkinson's patients: a randomized controlled trial Parkinson's diseasedual task training group :cognitive-cup-tapping balance training;single task training group:-cup-tapping balance training;control group:education;Shanghai University of SportNULLRecruiting4080Bothdual task training group :29;single task training group:29;control group:29;N/Achina
5NCT04591535
(ClinicalTrials.gov)
September 28, 202011/9/2020PK Study of WD-1603 in Healthy SubjectsAn Open Label, Balanced, Randomised, Four-treatment, Four-period, Four-sequence, Single Oral Dose, Crossover PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fed ConditionsParkinson DiseaseDrug: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETSHong Kong WD Pharmaceutical Co., LimitedNULLRecruiting18 Years45 YearsAll8Phase 1India
6NCT04553978
(ClinicalTrials.gov)
September 18, 202013/9/2020A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting ConditionsAn Open Label, Balanced, Randomised, 2-treatment, 2-period, 2-sequence, Single Oral Dose, Corssover Comparative PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fasting ConditionsParkinson DiseaseDrug: WD-1603Hong Kong WD Pharmaceutical Co., LimitedNULLNot yet recruiting18 Years45 YearsAll8Phase 1NULL
7ChiCTR2000035872
2020-09-012020-08-19Effect of repetitive transcranial magnetic stimulation on gait and balance function in patients with Parkinson's disease and Parkinson's syndromeEffect of repetitive transcranial magnetic stimulation on gait and balance function in patients with Parkinson's disease and Parkinson's syndrome Parkinson's disease and Parkinson's syndromeParkinson's disease observation group:Repetitive transcranial magnetic stimulation+Visual feedback balance training system+Digital treadmill ;Parkinson's disease control group:Visual feedback balance training system+Digital treadmill;Parkinson's syndrome observation group:Repetitive transcranial magnetic stimulation+Visual feedback balance training system+Digital treadmill;Parkinson's syndrome control group:Visual feedback balance training system+Digital treadmill ;Gansu Provincial HospitalNULLPending5085BothParkinson's disease observation group:28;Parkinson's disease control group:28;Parkinson's syndrome observation group:28;Parkinson's syndrome control group:28;China
8NCT04513340
(ClinicalTrials.gov)
August 13, 202012/8/2020WD-1603 PK Study Under Fasting and Fed Conditions in Healthy SubjectsAN OPEN LABEL, BALANCED, RANDOMISED, FOUR-TREATMENT, FOUR-PERIOD, FOUR-SEQUENCE, SINGLE INTRA-ORAL AND ORAL DOSE, CROSSOVER PHARMACOKINETICS STUDY OF WD-1603 EXTENDED-RELEASE CARBIDOPA/LEVODOPA TABLETS 25/100MG IN NORMAL, HEALTHY, ADULT HUMAN SUBJECTS UNDER FASTING AND FED CONDITIONSParkinson DiseaseDrug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETSHong Kong WD Pharmaceutical Co., LimitedNULLRecruiting18 Years45 YearsAll8Phase 1India
9ChiCTR2000034323
2020-08-012020-07-02The effect and correlation of rehabilitation training mode combined with visual feedback balance system and digital treadmill on three-dimensional Gait kinematics and diffusion tensor imaging in patients with early and mid period Parkinson's diseaseThe effect of rehabilitation training mode combined with visual feedback balance system and digital treadmill on Gait kinematics and diffusion tensor imaging in patients with early and mid period Parkinson's disease Parkinson's diseaseexperimental group:Combined Rehabilitation Training of visual feedback balance system and digital treadmill;control group:Traditional Gait Balance Rehabilitation Training;Xianhui FengNULLPendingBothexperimental group:30;control group:30;China
10NCT03661125
(ClinicalTrials.gov)
April 11, 20194/9/2018SRC Inhibition as a Potential Target for Parkinson's Disease PsychosisA Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.Parkinson Disease PsychosisDrug: Saracatinib;Drug: Placebo Oral TabletKing's College LondonAstraZeneca;King's College Hospital NHS TrustRecruiting40 YearsN/AAll30Early Phase 1United Kingdom
11JPRN-jRCTs052180158
19/07/201825/03/2019The effect of rehabilitation robots for patients with Parkinson's disease.A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient. Parkinson's Disease;D010300Robot group: The participants performs twelve per a session, 2sessions per a week for 8 weeks.
Control group: The participants receives balance exercise by physical therapist twice a week for 8 weeks.
Domen KazuhisaNULLComplete>= 40age old<= 80age oldBoth50N/AJapan
12JPRN-UMIN000033454
2018/07/0120/07/2018A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient.A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient. - A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient. Parkinson's Diseaserobot assisted balance training (RABT)
The group is taken 40-minute / session, twice a week during 8-weeks. Total intervention sessions are 16.
traditional balance training (TBT)
The group is taken 40-minute / session, twice a week during 8-weeks. Total intervention sessions are 16.
Hyogo College of MedicineNULLComplete: follow-up complete40years-old80years-oldMale and Female50Not selectedJapan
13ChiCTR2200057135
2018-04-042022-03-01Use of Wii Sports based training to reduce the falls and improve quality of life in people diagnosed as Parkinson's diseaseEffectiveness of Wii Sports Training on Postural Stability, Fall and Quality of Life in Idiopathic Parkinson’s Disease. Parkinson's DiseaseExperimental:Wii Sports based training;Control:Traditional Balance training;Alagumoorthi GandhisubramanianNULLCompleted4090BothExperimental:96;Control:96;N/AIndia
14ChiCTR-IPR-17011875
2017-08-012017-07-05Effects of Baduanjin Combined Balance Training on Gait and Posture Control of Patients with Mild and Moderate Parkinson's DiseaseEffects of Baduanjin Combined Balance Training on Gait and Posture Control of Patients with Mild and Moderate Parkinson's Disease Parkinson's DiseaseControl group:Conventional drug therapy;Baduanjin group:Baduanjin aerobic exercise;Balance function training group:Balance function training group;Affiliated Lianyungang Hospital of Xuzhou Medical UniversityNULLPending4080BothControl group:30;Baduanjin group:30;Balance function training group:30;China
15NCT03119194
(ClinicalTrials.gov)
January 27, 201713/4/2017Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067 in Healthy Male SubjectsParkinson DiseaseDrug: [14C]-BIA 9-1067Bial - Portela C S.A.NULLCompleted30 Years65 YearsMale7Phase 1United Kingdom
16NCT02879136
(ClinicalTrials.gov)
December 201623/6/2016TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's DiseaseTAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease: A Single Center, Randomized Pilot StudyParkinson's Disease, IdiopathicDrug: Methylphenidate;Other: Physical Therapy;Drug: AtomoxetineHubert FernandezNULLRecruiting18 Years90 YearsAll42Early Phase 1United States
17NCT02910102
(ClinicalTrials.gov)
October 201616/9/2016Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With DementiaA Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease DementiaAlzheimer's Disease;Dementia With Lewy Bodies;Parkinson's Disease DementiaDrug: RVT-101 35 mg;Drug: PlaceboAxovant Sciences Ltd.NULLCompleted50 Years89 YearsAll38Phase 2United States
18NCT02812147
(ClinicalTrials.gov)
May 201625/5/2016Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson DiseaseEffect of L-Dihydoxyphenylserine (L-DOPS, Northera) a Central and Peripheral Norepinephrine Agent on Locomotion, Postural Stability (Balance), and Fall Risk Reduction in Parkinson Disease (PD)Parkinson DiseaseDrug: L-DOPS;Drug: PlaceboSt. Joseph's Hospital and Medical Center, PhoenixArizona State University, TempeActive, not recruiting30 Years83 YearsAll20Phase 2United States
19JPRN-UMIN000016591
2015/04/0120/02/2015Clinical trial of balance exercise "Assist"Clinical trial of balance exercise "Assist" - Balance Exercise Assist Stroke, Parkinson disease, Osteoarthrosisuse of balance exercise assist
ordinary balance exercise
Juntendo UniversityNULLComplete: follow-up complete20years-old75years-oldMale and Female40Not applicableJapan
20NCT02206620
(ClinicalTrials.gov)
July 201429/7/2014Effects of Cholinergic Augmentation on Measures of Balance and GaitEffects of Cholinergic Augmentation on Measures of Balance and GaitParkinson's DiseaseDrug: DonepezilOregon Health and Science UniversityMichael J. Fox Foundation for Parkinson's ResearchCompleted30 YearsN/AAll49Phase 2United States
21NCT01521117
(ClinicalTrials.gov)
December 201112/1/2012The Effect of Donepezil on Gait and Balance in Parkinson's DiseaseA Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Effect of Donepezil on Gait and Balance in Parkinson's DiseaseParkinson's DiseaseDrug: DonepezilOregon Health and Science UniversityNULLRecruitingN/AN/ABoth12Phase 4United States
22NCT01119131
(ClinicalTrials.gov)
May 201123/4/2010Effects of Vitamin D in Parkinson's Disease (PD)The Effects of Vitamin D on Balance in Persons With PDParkinson Disease;Accidental FallsDrug: Vitamin D3;Dietary Supplement: calcium;Other: PlaceboVA Office of Research and DevelopmentOregon Health and Science UniversityCompleted50 Years99 YearsAll101Phase 2United States
23NCT01341080
(ClinicalTrials.gov)
December 28, 201021/4/2011Varenicline for Gait and Balance Impairment in Parkinson DiseaseVarenicline for the Treatment of Postural and Gait Dysfunction in Parkinson DiseaseParkinson DiseaseDrug: Varenicline;Drug: Sugar pillRush University Medical CenterNULLCompleted40 Years90 YearsAll40Phase 2United States